1,5-Anhydroglucitol in diabetes mellitus
- Authors
- Kim, WJ[Kim, Won Jun]; Park, CY[Park, Cheol-Young]
- Issue Date
- Feb-2013
- Publisher
- HUMANA PRESS INC
- Keywords
- 1,5-Anhydroglucitol; HbA1c; Diabetes mellitus; Gly
- Citation
- ENDOCRINE, v.43, no.1, pp.33 - 40
- Indexed
- SCIE
SCOPUS
- Journal Title
- ENDOCRINE
- Volume
- 43
- Number
- 1
- Start Page
- 33
- End Page
- 40
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/61638
- DOI
- 10.1007/s12020-012-9760-6
- ISSN
- 1355-008X
- Abstract
- The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications. However, HbA1c level neither accurately reflect glucose fluctuations, nor does it provide a clear indication of glycemic control in recent days or weeks. HbA1c concentration measurement can be confounded in patients with anemia, hemoglobinopathy, liver disease, or renal impairment. 1,5-Anhydroglucitol (1,5-AG) structurally resembles glucose. It can be influenced by diet or medication, gender and race, especially severe renal disease and various pathological conditions. Most notably, 1,5-AG level is reflective of short-term glucose status, postprandial hyperglycemia, and glycemic variability which are not captured by HbA1c assay. 1,5-AG may suggest an alternative index of subtypes of diabetes and a warning sign of diabetes complications. This review provides an overview of our current understanding of the role of 1,5-AG marker in diabetes. However, further investigations on the associations between this glycemic marker and diabetes complications are needed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.